GSK

GSK Settles U.S. Zantac Cancer Claims for $2.2 Billion, Boosting Stock by 6%

by

London – GSK’s stock soared by 6% on Thursday following the announcement that the British pharmaceutical giant has agreed to a multi-billion dollar settlement over allegations that its now-discontinued heartburn medication, Zantac, was carcinogenic. The company will pay up to $2.2 billion to resolve almost all the pending lawsuits in the United States, which is significantly lower than some financial analysts had anticipated. Previously, forecasts by entities such as JP Morgan had estimated potential liabilities to be as high as $3.5 billion. However, the settlement disclosed on Wednesday accounts for about 80,000 cases—or 93%—of the … Read more

Paul Weiss Strengthens Mass Torts Division by Recruiting Top Attorney from 3M, GSK

by

New York, NY – In a strategic expansion of its legal forces, Paul Weiss, a prominent law firm known for tackling high-profile lawsuits, has appointed a top lawyer from the corporate scene to enhance its ability to handle mass tort litigations. The move comes as the firm aims to strengthen its litigation team amid a surge in complex, multi-plaintiff cases. The newly recruited attorney, who previously represented major corporations such as 3M and GlaxoSmithKline (GSK), joins Paul Weiss with a wealth of experience in mass torts. These cases, which involve lawsuits with numerous plaintiffs against … Read more

Paul Weiss Bolsters Mass Torts Division with Top Lawyer from 3M and GSK

by

New York City, NY – Law firm Paul Weiss has appointed a new lawyer to join their mass torts team, with a focus on expanding their representation in the 3M and GSK cases. The move comes as the firm seeks to strengthen their presence in the litigation involving these two major companies. The lawyer, who has not been named, will bring extensive experience to the team. Their expertise in mass tort cases will be crucial in managing the complex legal challenges presented by the 3M and GSK litigations. Paul Weiss aims to enhance their capabilities … Read more

GSK Resolves Yet Another Zantac Legal Battle in California, Easing Concerns

by

San Francisco, California – Pharmaceutical company GlaxoSmithKline (GSK) has reached a settlement in yet another lawsuit regarding its popular heartburn medication, Zantac. The lawsuit was filed in California and alleged that the medication caused cancerous tumors in the plaintiff. GSK, based in the United Kingdom, has faced numerous lawsuits across the US concerning the potential link between Zantac and cancer. The settlement comes in the wake of recent studies that found the presence of a probable human carcinogen, NDMA, in ranitidine-based drugs like Zantac. The terms of the settlement were not disclosed, but GSK maintains … Read more